8000 Participants Needed

CA 125 Blood Test for Early Detection of Ovarian Cancer

Recruiting at 10 trial locations
SC
GH
Overseen ByGwen H. Corrigan
Age: 18+
Sex: Female
Trial Phase: Academic
Sponsor: M.D. Anderson Cancer Center
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial protocol does not specify whether you need to stop taking your current medications. However, if you are taking SERMS (like tamoxifen or aromatase inhibitors), you are not excluded from participating.

What data supports the effectiveness of this treatment for early detection of ovarian cancer?

Monitoring CA-125 levels over time can help detect ovarian cancer early, as it has shown a high specificity of 99.6% when used in serial measurements. However, its sensitivity is limited, and it may not detect all early-stage cancers, so it is most effective when combined with other screening methods.12345

Is the CA 125 blood test safe for humans?

The CA 125 blood test is generally considered safe for humans, but it is not recommended for routine screening of ovarian cancer due to potential harms and lack of evidence for effectiveness.678910

How does the CA 125 blood test differ from other treatments for ovarian cancer?

The CA 125 blood test is unique because it is not a treatment but a diagnostic tool used to detect ovarian cancer by measuring the level of a specific protein in the blood. Unlike treatments that aim to cure or manage the disease, this test helps in early detection, although it is not always reliable for all women, especially those with early-stage cancer or certain subtypes.1112131415

What is the purpose of this trial?

The goal of this clinical research study is to evaluate a method involving 4 blood tests called CA-125, HE4, HE4 antigen autoantibody complexes, and osteopontin that may be helpful in the early detection of ovarian cancer in women who are at low risk.

Research Team

DN

Denise Nebgen, MD, PHD

Principal Investigator

The University of Texas MD Anderson Cancer Center

Eligibility Criteria

This trial is for women aged 50-75 who are postmenopausal, have at least one ovary, and haven't had cancer or cancer treatments in the last year. Participants must be willing to take annual blood tests and possibly a transvaginal ultrasound if needed. They should not have conditions preventing informed consent, both ovaries removed, high genetic risk for ovarian cancer, or active non-ovarian malignancies.

Inclusion Criteria

Willingness to return for CA 125 blood tests annually or earlier if indicated
Willingness to return to undergo transvaginal ultrasound if indicated
I have not had a menstrual period for at least 12 months.
See 4 more

Exclusion Criteria

I have had both of my ovaries removed.
I am at high risk for ovarian cancer due to my family history.
I have an active cancer that is not ovarian cancer.
See 4 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks
1 visit (in-person)

Initial Assessment

Participants have blood drawn for CA-125 and other tumor markers, and complete medical and symptom questionnaires

1 day
1 visit (in-person)

Monitoring

Participants return for blood tests and possibly a transvaginal ultrasound based on CA-125 levels

Varies (3 months, 6 weeks, or 1 year)
1 visit every 3 months, 6 weeks, or 1 year (in-person)

Follow-up

Participants are monitored for safety and effectiveness after initial assessments and interventions

3 years
Annual visits (in-person)

Treatment Details

Interventions

  • Questionnaire
Trial Overview The study is testing whether a blood test called CA-125 can help detect ovarian cancer early in low-risk women. Participants will complete questionnaires and undergo regular CA-125 blood tests with follow-up procedures like ultrasounds if results suggest further examination is necessary.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: CA 125 AnalysisExperimental Treatment1 Intervention
Experimental: CA 125, HE4, HE4 antigen autoantibody complexes, and Osteopontin Analysis Participants will have blood (3-4 tablespoons) drawn for CA125 and other tumor markers. Depending on CA-125 level and other tumor markers: Blood (3-4 tablespoons) drawn for CA-125 testing and other tumor markers in 1 year. Blood (3-4 tablespoons) drawn for CA-125 testing and other tumor markers in 3 months, OR Blood (3-4 tablespoons) drawn for CA-125 testing and other tumor markers, and a transvaginal ultrasound in 6 weeks +/- 2 weeks.

Find a Clinic Near You

Who Is Running the Clinical Trial?

M.D. Anderson Cancer Center

Lead Sponsor

Trials
3,107
Recruited
1,813,000+

National Cancer Institute (NCI)

Collaborator

Trials
14,080
Recruited
41,180,000+

Golfers Against Cancer

Collaborator

Trials
2
Recruited
8,000+

Findings from Research

In a study of 100 ovarian cancer patients, a low pre-operative CA-125 level did not correlate with better survival outcomes, indicating it may not be a reliable prognostic marker.
Monitoring CA-125 levels during treatment was effective in assessing patient response, with significant decreases in CA-125 associated with better survival, and increases often indicating disease progression up to 9 months before clinical symptoms appeared.
CA-125 monitoring in the management of ovarian cancer.Bruzzone, M., Onetto, M., Campora, E., et al.[2004]
Screening for ovarian cancer using CA 125 and transvaginal sonography was found to increase average life expectancy by less than 1 day for a cohort of 40-year-old women in the U.S.
The minimal impact on life expectancy suggests that mass screening for ovarian cancer with these methods may not be an effective health policy.
The effectiveness of ovarian cancer screening. A decision analysis model.Schapira, MM., Matchar, DB., Young, MJ.[2022]
Current screening methods for ovarian cancer, such as CA 125 and transvaginal ultrasonography, have not been proven effective for widespread use to reduce mortality, and may even increase morbidity and mortality, highlighting the need for further research.
For early-stage ovarian cancer, women with stage IA grade 1 and most IB grade 1 do not need postoperative adjuvant therapy, while those with higher stages (II, III, and IV) should receive postoperative chemotherapy, emphasizing the importance of tailored treatment plans.
National Institutes of Health Consensus Development Conference Statement. Ovarian cancer: screening, treatment, and follow-up.[2022]

References

CA-125 monitoring in the management of ovarian cancer. [2004]
The effectiveness of ovarian cancer screening. A decision analysis model. [2022]
National Institutes of Health Consensus Development Conference Statement. Ovarian cancer: screening, treatment, and follow-up. [2022]
Status of tumor markers in ovarian cancer screening. [2016]
Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer. [2019]
Molecular signatures of ovarian cancer: from detection to prognosis. [2021]
Physician knowledge and awareness of CA-125 as a screen for ovarian cancer in the asymptomatic, average-risk population. [2016]
Development and validation of circulating CA125 prediction models in postmenopausal women. [2022]
Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer. [2022]
CA 125 as a screening test for ovarian cancer. [2017]
11.United Statespubmed.ncbi.nlm.nih.gov
The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: A population-based cohort study. [2021]
Multiple biomarker panels for early detection of ovarian cancer. [2015]
13.United Statespubmed.ncbi.nlm.nih.gov
The role of CA 125 in screening for ovarian cancer. [2022]
Salvaging Detection of Early-Stage Ovarian Malignancies When CA125 Is Not Informative. [2021]
CA125 test result, test-to-diagnosis interval, and stage in ovarian cancer at diagnosis: a retrospective cohort study using electronic health records. [2021]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of ServiceยทPrivacy PolicyยทCookiesยทSecurity